Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Supernus receives FDA fast track designation for SPN-810
This product candidate is expected to enter Phase III testing, with patient dosing commencing during 2015. Fast track designation is for products that are being investigated for treatment
This product candidate is expected to enter Phase III testing, with patient dosing commencing during 2015. Fast track designation is for products that are being investigated for treatment
The acquisition is expected to be immediately accretive to Mallinckrodt’s fiscal 2014 adjusted diluted earnings per share and significantly accretive to its adjusted diluted earnings per share in
The title of the publication is "Encapsulated Cells Expressing a Chemotherapeutic Activating Enzyme Allow the Targeting of Subtoxic Chemotherapy and Are Safe and Efficacious: Data from Two Clinical
The patent covers a wide range of liquid formulations for the prevention and treatment of mucosal diseases and disorders. "Following our recent European licensing agreement with Norgine, the
The study will focus on a medical syndrome, which according to a mounting tide of scientific research is having a debilitating effect on the health and vitality of
The issued patent claims cover systems for determining the activation state of more than one protein in a cell, where the system can utilize any detector, including cytometers
The acquisition further strengthens Miltenyi Biotec’s portfolio in cell and gene therapy. Assets obtained in the transaction include a broad range of intellectual property, process technologies, and cGMP-qualified
The parallel-group, single-dose study met the criteria for clinical PK similarity on all three required, prospectively defined, PK endpoints: maximum serum concentration (Cmax), area under the time-concentration curve
RP101 is a proprietary, first-in-class, heat shock protein 27 (Hsp27) inhibitor, administered orally, which may prevent the induction of resistance to chemotherapy (chemoresistance), thus maintaining sensitivity of the
The signing of the supplemental agreement accelerates clinical trial development in both America and China, for IRT-101 ("MENK"). In the hope of moving clinical development forward the parties